SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer (LU)

Prolong Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Leg Ulcer

Treatments: Biological: SANGUINATE

Study type: Interventional

Funder types: Industry

Identifiers

NCT02600390

SGSC-009

Details and patient eligibility

About

SANGUINATE™ Sickle Cell Disease associated Leg Ulcers.

Full description

This is an escalating, repeated-dose, open-label Phase 2 study to test SANGUINATE (pegylated carboxyhemoglobin bovine) in patients suffering from leg ulceration associated with Sickle Cell Disease (SCD leg ulcer).

Patients will undergo consent and screening procedures at the time of presentation for leg ulcer treatment. Eligible patients will begin a 3-week Run-In Period. A total of approximately fifteen (15) patients are expected to be screened in order to achieve an enrollment target of ten (10) evaluable patients for participation in the study. Evaluable is defined as a patient receiving a minimum of three doses of investigational product. Five (5) patients (Cohort 1) will receive four (4) once-weekly 2-hour IV infusions of SANGUINATE at a dose of 320 mg/kg (8 mL). An additional five (5) patients (Cohort 2) will receive six (6) once-weekly 2-hour IV infusions of SANGUINATE also at a dose of 320 mg/kg. Each patient will be contacted by telephone approximately 24 hours after dosing to verify the safety status of the patient. One week following the Treatment Phase, patients will return to the study center for a Final Visit where safety assessments will be performed. During the Final Visit, patients will receive standard of care treatment of ulcer. All patients will receive once-weekly Standard of Care (SOC) therapy for SCD leg ulcer for the duration of the study. SOC includes dressing the wound with multi-layer, short stretch, compression bandaging. Non-adherent, medical-grade foam will be used as the wound contact layer and primary dressing.

Enrollment: 10 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Properly consented patients suffering from Sickle Cell Disease (Hb-SS or Hb- Sβ° genotype) associated Leg ulcer.
• Presence of leg ulcer for at least 4 weeks
• Venous Clinical Severity Score of moderate to severe (defined as ≥12)
• Leg ulcer below the knee

Exclusion criteria

• Patient presenting with a clinically & laboratory confirmed bacterial, fungal or acid fast organisms
• Patient has a recent acute complication of Sickle Cell Disease (e.g., pain crisis within 7 days, or acute chest syndrome within 21 days)
• Patient is planning to be pregnant, is pregnant, or is breast-feeding
• Presence of moderate to severe renal insufficiency (CrCl < 30 mL/min) or chronic kidney disease, or of moderate to severe hepatic insufficiency (Child-Pugh class B or C)
• Patients with more than 3 times the upper limit of normal laboratory reference range
• Concurrent or recent prior treatment (within 90 days) with an investigational medication
• Patients currently receiving treatment with hydroxyurea must be on stable dose for at least 30 days
• Receipt of a blood transfusion within 21 days

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

10 participants in 2 patient groups

SANGUINATE™ (4-week)

Experimental group

Description:

This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.

Treatment:

Biological: SANGUINATE

SANGUINATE™ (6-week)

Experimental group

Description:

This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.

Treatment:

Biological: SANGUINATE